David R. Janero
Professor (Adjunct Faculty) and Deputy Director
Department: Center for Drug Discovery
Department 2: School of Pharmacy
Office: 116 Mugar Hall
 
Résumé/CV

Phone: 617-373-2208
Fax: 617-373-7493
Email: d.janero@neu.edu

 
 
Education:  
B.A., Biology, Boston University 
Ph.D., Cell Biology and Molecular Physiology, Yale University School of Medicine
Postdoctoral Fellow, Physiological Chemistry, Johns Hopkins University School of Medicine 

Specializations:   
Biochemistry
Molecular and Cellular Biology
Pharmacology 
Pathology
Biotechnology and Pharmaceutical Industries
Translational and Entrepreneurial Science
Pharmaceutical and Biotechnology Consulting

Research:  
Metabolism and bioenergetics
Enzyme and receptor biology
Signal transduction
Molecular medicine
Mechanisms of disease and drug action
Biomarker discovery, validation, and application
Integrative and systems biology
Disease modeling
Discovery, profiling, and development of drugs and therapeutic devices

Other Affiliations: 
Massachusetts Institute of Technology, Venture Mentoring Service
Boston University School of Medicine, Research Associate Professor (Adjunct), Biochemistry

Publications:  
Crowley, H.J., B. Yaremko, W.M. Selig, D.R. Janero, C. Burghardt, A.F. Welton and M. O'Donnell.  1991.  Pharmacology of a novel platelet-activating factor (PAF) antagonist:  Ro 24-4736.  J. Pharmacol. Exp. Ther.  259:78-85.
Ross, J., D.R. Janero and D. Hreniuk.  1993.  Identification and biochemical characterization of a heart-muscle cell transforming growth factor-b1 receptor.  Biochem. Pharmacol.  46:511-516.
Sandhu, G.S., A.C. Burrier and D.R. Janero.  1993.  Adenosine deaminase inhibitors attenuate ischemic injury and preserve energy balance in isolated guinea-pig heart.  Am. J. Physiol.  265:H1249-H1256.
Thakkar, J.K., D.R. Janero, H.M. Sharif, D. Hreniuk and C. Yarwood.  1994.  Cardiac adenylate deaminase:  molecular, kinetic, and regulatory properties under phosphate-free conditions.  Biochem. J. 300:359-363.
Janero, D.R. and D. Hreniuk.  1996.  Suppression of TCA cycle activity in the cardiac muscle cell by hydroperoxide-induced oxidant stress.  Am. J. Physiol.  270:C1735-C1742.
Bandarage, U.K., L Chen, X. Fang, D.S. Garvey, A. Glavin, D.R. Janero, L.G. Letts, G.J. Mercer, J.K. Saha, J.D. Schroeder, M.J. Shumway and S.W. Tam.  2000.  Nitrosothiol esters of diclofenac:  synthesis and pharmacological characterization as gastrointestinal-sparing prodrugs.  J. Med. Chem.  43:4005-4016.
Lin, C.-E., D.S. Garvey, D.R. Janero, L.G. Letts, P. Marek, S.K. Richardson, D. Serebryanik, M.J. Shumway, S.W. Tam, A.M. Trocha and D.V. Young.  2004.  Combination of paclitaxel and nitric oxide as a novel treatment for the reduction of restenosis.  J. Med. Chem.  47:2276-2282.
Janero, D.R., N.S. Bryan, F. Saijo, V. Dhawan, D.J. Schwalb, M.C. Warren and M. Feelisch.  2004.  Differential nitros(yl)ation of blood and tissue constituents during glyceryl trinitrate biotransformation in vivo.  Proc. Natl. Acad. Sci. USA  101:16958-16963.
Khanapure, S.P., M.E. Augustyniak, R.A. Earl, D.S. Garvey, L.G. Letts, A.M. Martino, M.G. Murty, D.J. Schwalb, M.J. Shumway, A.M. Trocha, D.V. Young and D.R. Janero.  2005.  3-[4-(Methylsulfonyl)phenyl]-5-(trifluoromethyl)(2-pyridyl) phenyl ketone as a potent and orally active cyclooxygenase-2 (COX-2) selective inhibitor:  synthesis and biological evaluation.  J. Med. Chem.  48:3930-3934.
Dhawan, V., D.J. Schwalb, M.J. Shumway, M.C. Warren, R.S. Wexler, I.S. Zemtseva and D.R. Janero.  2005.  Selective nitros(yl)ation induced in vivo by a nitric oxide-donating cyclooxygenase-2 inhibitor:  a NObonomic analysis.  Free Radical Biol. Med.  39:1191-1207.
Lin, C.-E., D.R. Janero and D.S. Garvey.  2005.  Nitric oxide (NO)-based molecular strategies for restenosis therapy.  Exp. Opin. Ther. Patents  15:483-495.
Khanapure, S.P., D.S. Garvey, D.R. Janero and L.G. Letts.  2007.  Eicosanoids in inflammation:  biosynthesis, pharmacology, and therapeutic frontiers.  Curr. Topics Med. Chem.  7:311-340.
Janero, D.R. and A. Makriyannis.  2007.  Targeted modulators of the endogenous cannabinoid system:  future medications to treat addiction disorders and obesity.  Curr. Psychiatry Rep.  9:365-373.
Vemuri, V.K., D.R. Janero and A. Makriyannis.  2007.  Pharmacotherapeutic targeting of the endocannabinoid signaling system:  drugs for obesity and the metabolic syndrome.  Physiol. Behav.  doi:10.1016/j.psysbeh.2007.11.012.
Wey, S.J., M.E. Augustyniak, E.D. Cochran, J.L. Ellis, X. Fang, D.S. Garvey, D.R. Janero, et al.  2007.  Structure-based design, synthesis, and biological evaluation of indomethacin derivatives as cyclooxygenase-2 inhibiting nitric oxide donors. J. Med. Chem. 50:6367-6382.
Zvonok, N.,  J. Williams, M. Johnston, L. Pandarinathan, D.R. Janero, J. Li, S.C. Krishnan and A. Makriyannis. 2008.  Full mass spectrometric characterization of human monoacylglycerol lipase generated by large-scale expression and single-step purification.  J. Proteome Res.  In press.


 
[Back to Directory]
 
Manage